Originally posted here:
Telesis Bio Pre-Announces Preliminary Fourth Quarter Financial Results

Excerpt from:
NGM Bio Outlines Corporate Strategy and Provides Guidance on Key Priorities

Excerpt from:
Biora Therapeutics Receives Pre-IND Feedback from FDA and Provides Update on Key Programs for 2023

View original post here:
First Wave BioPharma Announces Adjournment of Special Meeting

More here:
Derm-Biome Pharmaceuticals’ Multi-Target Topical Drug Produces Positive Results in Preclinical Study in Acne

Continued here:
Number of voting rights as of January 9, 2023

Read the original:
Monthly information related to total number of voting rights and shares composing the share capital _December 31, 2022

Go here to read the rest:
Revive Therapeutics Announces Publication Showing Bucillamine’s Potential Impact on COVID-19 Omicron Variants

More here:
MDxHealth Reports Preliminary 2022 Revenues and Reaffirms 2023 Revenue Guidance

Go here to see the original:
VYNE Therapeutics Announces First Vitiligo Patient Dosed in Phase 1a/b Clinical Trial of Novel BET Inhibitor VYN201

Read more:
Sutro Biopharma Announces Update from STRO-002, Luveltamab Tazevibulin (Luvelta), Phase 1 Dose-Expansion Study and Registrational Plans in Advanced...

Read more:
Bright Minds Biosciences Announces Resignation of Board Member

See the rest here:
ImmuCell Announces Preliminary, Unaudited Sales Results for the Year Ended December 31, 2022

Original post:
Assertio Holdings, Inc. Announces FDA Orange Book Listing for New Sympazan® Oral Film Patent

Read the original:
Lifecore Biomedical Raises Capital with Private Placement of Convertible Preferred Stock; Amends Credit Facilities

Read more:
BeyondSpring Receives Notifications from Nasdaq Regarding Compliance With Listing Rules

See original here:
Syneos Health Announces Chief Financial Officer Transition

Read this article:
Nkarta Promotes David R. Shook, M.D., to Chief Medical Officer

View original post here:
Psyence Announces Business Combination between Wholly Owned Subsidiary Psyence Biomed Corp. and Nasdaq listed Newcourt Acquisition Corp

See original here:
MediciNova Receives a Notice of Allowance for a New Patent Covering MN-001 and MN-002 for the Treatment of Hypertriglyceridemia, Hypercholesterolemia,...